Rupali Bhardwaj


Van der Maasweg 9, 2629 HZ Delft 

Tel: *31 (0)15-2786300

Development of a MOF based 177mLu/177Lu generator to provide access to 177Lu

177Lu is used as therapeutic agent in Peptide receptor radionuclide therapy for the treatment of neuroendocrine tumours. It is a promising alternative to conventional therapies since it actively targets tumour cells, thereby concentrating radioactivity in the diseased cells. [1]. A growing problem in lutetium PRRT is the insufficient purity and insufficient activity of 177Lu obtained by the conventional production routes.[2] These shortcomings call for new alternatives. A 177mLu/177Lu generator can provide instant and reactor independent access to ultra-high specific 177Lu. [3]. The goal of this research project is to investigate the possibility of a 177mLu based MOF to generate ultra-high specific 177Lu.


[1] G. A. Kaltsas, D. Papadogias, P. Makras and A. B. Grossman, Endocr Relat Cancer December 1, 2005 12 683-699

[2] Wouter A. P. Breeman, Marion de Jong, Theo J. Visser,  Jack L. Erion,  Eric P. Krenning,  European Journal of Nuclear Medicine and Molecular Imaging June 2003, Volume 30, Issue 6, pp 917-920.

[3] De Vries, DJ & Wolterbeek, HT (2012)Tijdschrift voor Nucleaire Geneeskunde, 34(2), 899-904.